Soo Aleman
Karolinska University Hospital · 308 works · 15,674 citations · h-index 44
Top works
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
- Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
- The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
- Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
- Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
- Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
- Historical epidemiology of hepatitis C virus ( HCV ) in selected countries
- A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver Cirrhosis
- Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
- Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
- Strategies to manage hepatitis C virus ( HCV ) disease burden
- Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
- A multinational Delphi consensus to end the COVID-19 public health threat
- Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
- Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
- Natural killer cell immunotypes related to COVID-19 disease severity
- A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
- Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy
- Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial